Generic Name and Formulations:
Dapsone 5%; gel.
Indications for ACZONE:
Wash skin and pat dry. Apply pea-sized amount to affected area in a thin layer twice daily in the AM & PM. Rub in gently and completely. Wash hands after use. Reevaluate if no improvement after 12 weeks.
Avoid in congenital or idiopathic methemoglobinemia. G6PD deficiency: may have increased risk of methemoglobinemia or hemolytic anemia; discontinue if occurs. Pregnancy (Cat.C). Nursing mothers: not recommended.
Increased risk of hemolysis in G6PD-deficient patients with concomitant trimethoprim/sulfamethoxazole, other folic acid antagonists (eg, pyrimethamine), anticonvulsants, rifampin, St. John's wort. Increased risk of methemoglobinemia with concomitant sulfonamides, acetaminophen, chloroquine, nitrates, nitrites, nitrofurantoin, phenobarbital, phenytoin, primaquine, quinine, and others. Skin/hair discoloration with topical benzoyl peroxide.
Application site reactions (oiliness, peeling, dryness, erythema, pruritus).
Gel 5% (tubes)—60g, 90g; Gel 7.5% (pumps)—30g, 60g, 90g
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- NSCLC: Pretreatment Weight Loss May Be Linked to Socioeconomic Status
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- Atezolizumab, Carboplatin, Nab-Paclitaxel Combination Prolongs PFS in NSCLC